CDK7 and prostate carcinoma: These data propose that CDK7 inhibitors could be combined with the mainstream prostate cancer therapy, anti-androgens: this treatment strategy should target both the androgen-dependent prostate cancer cells and the CRPC cells but have minimal effects on the normal cells of the body.